123 related articles for article (PubMed ID: 28785994)
1. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M; Mori K; Iida T; Kurihara K; Saitou M; Tokunaga H; Kawana K; Ikeda M; Satoh T; Saito T; Miyagi E; Nagai Y; Furusawa A; Kawano Y; Kawano K; Tabata T; Ota Y; Hayase R; Mikami M; Sugiyama T
Cancer Chemother Pharmacol; 2017 Oct; 80(4):697-705. PubMed ID: 28785994
[TBL] [Abstract][Full Text] [Related]
2. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
3. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
Matoda M; Tanigawa T; Omatsu K; Ushioda N; Yamamoto A; Okamoto S; Kawamata Y; Kato K; Umayahara K; Takeshima N
Int J Gynecol Cancer; 2013 Nov; 23(9):1670-4. PubMed ID: 24172102
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
5. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.
Tanioka M; Katsumata N; Yonemori K; Kouno T; Shimizu C; Tamura K; Ando M; Fujiwara Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):337-42. PubMed ID: 20976599
[TBL] [Abstract][Full Text] [Related]
6. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
7. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M; Yunokawa M; Bun S; Miyasaka N; Kato T; Tamura K
Cancer Chemother Pharmacol; 2019 Jul; 84(1):33-39. PubMed ID: 30982097
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Murata S; Onozawa S; Sugihara F; Sakamoto A; Ueda T; Yamaguchi H; Yasui D; Mine T; Kumita S
Ann Surg Oncol; 2015 Nov; 22(12):3981-9. PubMed ID: 25758191
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital: Thailand's Largest Tertiary Referral Center.
Ruengkhachorn I; Leelaphatanadit C; Therasakvichya S; Hunnangkul S
Int J Gynecol Cancer; 2016 Jul; 26(6):1154-61. PubMed ID: 27051060
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
12. Retention of platinum sensitivity till late stages of tumour progression may imply improved prognosis of oesophageal and gastric cancers.
Hingorani M; Dixit S; Roy R; Maraveyas A
Oncol Res Treat; 2015; 38(1-2):28-34. PubMed ID: 25634795
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix.
Eralp Y; Saip P; Sakar B; Kucucuk S; Aydiner A; Dincer M; Aslay I; Topuz E
Int J Gynecol Cancer; 2003; 13(4):497-504. PubMed ID: 12911727
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
[TBL] [Abstract][Full Text] [Related]
16. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol.
Chambers SK; Lamb L; Kohorn EI; Schwartz PE; Chambers JT
Gynecol Oncol; 1994 May; 53(2):161-9. PubMed ID: 7514557
[TBL] [Abstract][Full Text] [Related]
19. The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy.
Kastritis E; Bamias A; Bozas G; Koutsoukou V; Voulgaris Z; Vlahos G; Rodolakis A; Gika D; Papadimitriou C; Dimopoulos MA
Gynecol Oncol; 2007 Feb; 104(2):372-6. PubMed ID: 17030353
[TBL] [Abstract][Full Text] [Related]
20. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Dockery LE; Rubenstein AR; Ding K; Mashburn SG; Burkett WC; Davis AM; Doo DW; Arend RC; Moore KN; Gunderson CC
Gynecol Oncol; 2019 Nov; 155(2):201-206. PubMed ID: 31522837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
